BioMedical Ventures

General information


Bilthoven, Utrecht


Aglaia is founded on the principle that the willingness to take risks on the very early stage ventures of today results in opportunities that may grow into the winning companies of tomorrow. As such, we are typically the first provider of capital for startup and early stage companies and a driving force behind product development.

Since the number of technological discoveries in the biomedical field is growing fast, specialized knowledge regarding the translation of these discoveries into novel products is a prerequisite for success. Aglaia’s focus on oncology is considered to be a differentiating asset. We invest in novel tools and technologies as well as components of contemporary drug development.

Opportunities may be derived from research centers as well as from corporate spinouts. We select, develop and commercialize promising technologies up to a level where the technology becomes attractive to larger investors or pharmaceutical and biotech companies.


Mark Krul (Founder, PhD, Partner)


Karl Rothweiler (MBA, Partner), Eric van der Putten (BSc, Partner), Winald Gerritsen (MD, PhD, Venture Partner), Ernst Geutjes (PhD, Associate), Angelique Hermelin (Office Manager)


Contact information

Investment information

Investment type

Seed investments, early stage venture investments

Investment size

500k – 2.5M

Investing in

Health, biomedical, oncology

Investments made

InteRNA Technologies, Inthera Bioscience, ISA Pharmaceuticals, Merus, Modra Pharmaceuticals, ORCA Pharmaceuticals, ORCA Therapeutics, Somanix, Syntarga


Syntarga (Acquired by Synthon)